RITONAVIR

Ritonavir is a protease inhibitor used in HIV therapy and as a CYP3A inhibitor to boost other antivirals. Side effects include nausea, diarrhea, lipid abnormalities, hepatotoxicity, and drug interactions. Only GMP materials will be supplied, logistics all according to GDP.

SKU: b4248044b6f1 Category: Tag:

Product Description


Mechanism of Action

RITONAVIR engages in multilayer biochemical interactions affecting enzyme cascades, receptorregulated signalling, oxidativestress systems, mitochondrial respiration, ionchannel dynamics, cytoskeletal mechanics and transcriptionfactor pathway coordination. Molecularmodelling parameters suggest potential interactions with catalytic centres, allosteric microdomains, transmembrane receptor helices, cofactorbinding regions, and structural scaffolding proteins. These interactions enable modulation of phosphorylation cycles, secondmessenger amplification (Ca²⁺, cAMP, IP, DAG), ATP turnover, mitochondrial membrane potential and ROS balancing capacity.

Benefits and Applications

  • Receptorligand affinity mapping and molecular docking
  • Enzymekinetic pathway modelling and catalyticflux analysis
  • Mitochondrial bioenergetics profiling and redoxstate research
  • Multiomics studies (transcriptomics, metabolomics, proteomics)
  • Cytoskeletal architecture analysis and membranedynamics modelling
  • Apoptosis, necroptosis, autophagy and ferroptosis pathway assays
  • SAR and QSARdriven molecular optimisation
  • Pharmacodynamic and mechanistic doseresponse modelling

Risks & Side Effects

  • Oxidative imbalance and ROS escalation
  • Mitochondrial overload or suppression of respiratory complexes
  • Ionchannel destabilisation (Na⁺/K⁺/Ca²⁺)
  • Unintended receptor crosstalk
  • Cytoskeletal destabilisation
  • Dosedependent cytotoxicity or programmed-cell-death activation
  • Inflammatory transcriptional activation (NF-κB, JNK, MAPK)

Only GMP materials will be supplied, logistics all according to GDP.

Datasheet


Molecular Formula

C37H48N6O5S2

Molecular Weight

720.9 g/mol

CAS Number

155213-67-5

Storage Condition

Commercially available ritonavir oral solution should be stored at room temperature at 20-25C; the oral solution should not be refrigerated. Exposure to excessive heat should be avoided. Ritonavir oral solution should be stored in the manufacturer-provided amber bottle and protected from light.

Solubility

Practically insoluble

Purity

Purity information is available upon request (COA).

Synonym

ritonavir; 155213-67-5; Norvir; ABT-538; A-84538

IUPAC/Chemical Name

1,3-thiazol-5-ylmethyl N-[(2S,3S,5S)-3-hydroxy-5-[[(2S)-3-methyl-2-[[methyl-[(2-propan-2-yl-1,3-thiazol-4-yl)methyl]carbamoyl]amino]butanoyl]amino]-1,6-diphenylhexan-2-yl]carbamate

InChl Key

NCDNCNXCDXHOMX-XGKFQTDJSA-N

InChl Code

InChI=1S/C37H48N6O5S2/c1-24(2)33(42-36(46)43(5)20-29-22-49-35(40-29)25(3)4)34(45)39-28(16-26-12-8-6-9-13-26)18-32(44)31(17-27-14-10-7-11-15-27)41-37(47)48-21-30-19-38-23-50-30/h6-15,19,22-25,28,31-33,44H,16-18,20-21H2,1-5H3,(H,39,45)(H,41,47)(H,42,46)/t28-,31-,32-,33-/m0/s1

References

https://pubchem.ncbi.nlm.nih.gov/compound/392622;

3D Conformer.

(Click, turn or enlarge)

Download our GMP API Product List.

MedicaPharma is an EU-based supplier of GMP-certified APIs that serves leading healthcare institutions and research organizations.
Click here to download our full API product list.

Download